A new kind of scan for patients with a lymphoma in the central nervous system
- Conditions
- central nervous system localized malignant lymphoma.Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Registration Number
- EUCTR2015-000056-23-NL
- Lead Sponsor
- MC Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
-Patients who have signed informed consent
-Age = 18 years
-MR suspicion of a primary CNS lymphoma (homogeneous contrast enhancement, low MRI ADC values).
-Planned diagnostic biopsy
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 8
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 2
Exclusion Criteria
-Pregnancy
-Contra-indications for brain biopsy e.g. coagulation disorder or poor clinical condition assessed as unfit for surgical procedure.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: The objective of the study is to confirm that PCNSL is positive on 89Zr-rituximab PET imaging.;Secondary Objective: Not applicable;Primary end point(s): The main outcome of the study is the performance of 89Zr- rituximab PET/CT in diagnosing CSN lymphoma. ;Timepoint(s) of evaluation of this end point: 2 weeks
- Secondary Outcome Measures
Name Time Method Secondary end point(s): not applicable;Timepoint(s) of evaluation of this end point: not applicable